apo-amisulpride
apotex nz ltd - amisulpride 100mg; - tablet - 100 mg - active: amisulpride 100mg excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian
sanofi-aventis new zealand limited - amisulpride 100 mg/ml; - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
solian amisulpride 100mg/ml oral solution bottle
sanofi-aventis australia pty ltd - amisulpride, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: methyl hydroxybenzoate; hydrochloric acid; propyl hydroxybenzoate; purified water; potassium sorbate; saccharin sodium; gluconolactone; sodium gluconate; flavour - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride winthrop
sanofi-aventis new zealand limited - amisulpride 100 mg/ml; - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml excipient: caramel gesweet (vanillin, ethanol, propylene glycol & acetoin) hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water
amisulpride
focus pharmaceuticals ltd - amisulpride - oral solution - 100 mg/ml - amisulpride
amisulpride thame 100mg/ml sugar free oral solution
syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - amisulpride - oral solution - amisulpride 100 mg/ml - psycholeptics
amisulpride 100mg/ml oral solution sugar free
advanz pharma - amisulpride - oral solution - 100mg/1ml
apo-amisulpride 100 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apo-amisulpride 200 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; methylcellulose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apo-amisulpride 50 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.